rcc4 Search Results


anti dirc2 antibody  (Proteintech)
92
Proteintech anti dirc2 antibody
Lollipop chart for immune cell infiltration with <t>DIRC2</t> (A) and MCEMP1 (B). Line graph GSEA analysis for the top five pathways of DIRC2 (C) and MCEMP1 (D).
Anti Dirc2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rcc4/DIRC2+Antibody/pmc11438437-76-1-6
Average 92 stars, based on 1 article reviews
anti dirc2 antibody - by Bioz Stars, 2026-09
92/100 stars
  Buy from Supplier
rcc4-va  (DS Pharma Biomedical)
90
DS Pharma Biomedical rcc4-va
Lollipop chart for immune cell infiltration with <t>DIRC2</t> (A) and MCEMP1 (B). Line graph GSEA analysis for the top five pathways of DIRC2 (C) and MCEMP1 (D).
Rcc4 Va, supplied by DS Pharma Biomedical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rcc4/rcc4+va/pmc05996370-41-9-33
Average 90 stars, based on 1 article reviews
rcc4-va - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rcc4 plus pvhl  (European Collection of Authenticated Cell Cultures)
90
European Collection of Authenticated Cell Cultures rcc4 plus pvhl
Lollipop chart for immune cell infiltration with <t>DIRC2</t> (A) and MCEMP1 (B). Line graph GSEA analysis for the top five pathways of DIRC2 (C) and MCEMP1 (D).
Rcc4 Plus Pvhl, supplied by European Collection of Authenticated Cell Cultures, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rcc4/rcc4+cell+line/pmc06892797-64-9-17
Average 90 stars, based on 1 article reviews
rcc4 plus pvhl - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rcc4-ev cells  (Cancer Research Technology Limited)
90
Cancer Research Technology Limited rcc4-ev cells
Lollipop chart for immune cell infiltration with <t>DIRC2</t> (A) and MCEMP1 (B). Line graph GSEA analysis for the top five pathways of DIRC2 (C) and MCEMP1 (D).
Rcc4 Ev Cells, supplied by Cancer Research Technology Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rcc4/rcc4+ev+cells+harbor+inactivating+vhl+mutation/pmc05794101-213-0-12
Average 90 stars, based on 1 article reviews
rcc4-ev cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rcc4(-) cells  (KAC Co Ltd)
90
KAC Co Ltd rcc4(-) cells
Effects of 15d-PGJ 2 on the anti-cancerous activities of topoisomerase inhibitors in <t>RCC4</t> (-) cells . RCC4 (-) cells were treated with CPT (A), VP-16 (B), DOX (C) or 15d-PGJ 2 (D) at the indicated concentrations for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). *P < 0.05, compared with control, **P < 0.01, compared with control. (E) RCC4 (-) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence (open column) or presence (closed column) of 20 μM 15d-PGJ 2 for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). **P < 0.01, compared with control. (F) RCC4 (-) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence or presence of 20 μM 15d-PGJ 2 for 24 h. Morphologies were photographed by phase contrast. Scale bar = 100 µm.
Rcc4( ) Cells, supplied by KAC Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rcc4/rcc4++++cells/pmc06377412-32-2-7
Average 90 stars, based on 1 article reviews
rcc4(-) cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rcc lines rcc4  (DDC Medical)
90
DDC Medical rcc lines rcc4
Effects of 15d-PGJ 2 on the anti-cancerous activities of topoisomerase inhibitors in <t>RCC4</t> (-) cells . RCC4 (-) cells were treated with CPT (A), VP-16 (B), DOX (C) or 15d-PGJ 2 (D) at the indicated concentrations for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). *P < 0.05, compared with control, **P < 0.01, compared with control. (E) RCC4 (-) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence (open column) or presence (closed column) of 20 μM 15d-PGJ 2 for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). **P < 0.01, compared with control. (F) RCC4 (-) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence or presence of 20 μM 15d-PGJ 2 for 24 h. Morphologies were photographed by phase contrast. Scale bar = 100 µm.
Rcc Lines Rcc4, supplied by DDC Medical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rcc4/rcc+lines+rcc4/pmc04873412-77-0-19
Average 90 stars, based on 1 article reviews
rcc lines rcc4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human renal carcinoma rcc4  (CEM Corporation)
90
CEM Corporation human renal carcinoma rcc4
Effects of 15d-PGJ 2 on the anti-cancerous activities of topoisomerase inhibitors in <t>RCC4</t> (-) cells . RCC4 (-) cells were treated with CPT (A), VP-16 (B), DOX (C) or 15d-PGJ 2 (D) at the indicated concentrations for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). *P < 0.05, compared with control, **P < 0.01, compared with control. (E) RCC4 (-) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence (open column) or presence (closed column) of 20 μM 15d-PGJ 2 for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). **P < 0.01, compared with control. (F) RCC4 (-) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence or presence of 20 μM 15d-PGJ 2 for 24 h. Morphologies were photographed by phase contrast. Scale bar = 100 µm.
Human Renal Carcinoma Rcc4, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rcc4/human+renal+carcinoma+rcc4/pm18474260-98-11-7
Average 90 stars, based on 1 article reviews
human renal carcinoma rcc4 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
rcc4 whole cell lysate  (Novus Biologicals)
N/A
   Buy from Supplier

Image Search Results


Lollipop chart for immune cell infiltration with DIRC2 (A) and MCEMP1 (B). Line graph GSEA analysis for the top five pathways of DIRC2 (C) and MCEMP1 (D).

Journal: PeerJ

Article Title: Identification of a novel immune infiltration-related gene signature, MCEMP1 , for coronary artery disease

doi: 10.7717/peerj.18135

Figure Lengend Snippet: Lollipop chart for immune cell infiltration with DIRC2 (A) and MCEMP1 (B). Line graph GSEA analysis for the top five pathways of DIRC2 (C) and MCEMP1 (D).

Article Snippet: The anti- DIRC2 antibody (1:1,000, 26750-1-AP; Proteintech), anti- MCEMP1 antibody (1:3,000, 25700-1-AP, proteintech), anti-ICAM1 antibody (1:500, 200350-F12; ZEN BIO), and anti-GAPDH antibody (1:2,000, 60004-1-Ig; Proteintech) were used in this study.

Techniques:

(A) The mRNA and protein expression of DIRC2 and MCEMP1 in ox-LDL-treated HUVECs by qRT‐PCR assay and Western blot assay. * p < 0.05; ** p < 0.01; *** p < 0.001. ox-LDL, oxidized low-density lipoprotein; HUVECs, human umbilical vein endothelial cells; qRT‐PCR, quantitative real‐time polymerase chain reaction.

Journal: PeerJ

Article Title: Identification of a novel immune infiltration-related gene signature, MCEMP1 , for coronary artery disease

doi: 10.7717/peerj.18135

Figure Lengend Snippet: (A) The mRNA and protein expression of DIRC2 and MCEMP1 in ox-LDL-treated HUVECs by qRT‐PCR assay and Western blot assay. * p < 0.05; ** p < 0.01; *** p < 0.001. ox-LDL, oxidized low-density lipoprotein; HUVECs, human umbilical vein endothelial cells; qRT‐PCR, quantitative real‐time polymerase chain reaction.

Article Snippet: The anti- DIRC2 antibody (1:1,000, 26750-1-AP; Proteintech), anti- MCEMP1 antibody (1:3,000, 25700-1-AP, proteintech), anti-ICAM1 antibody (1:500, 200350-F12; ZEN BIO), and anti-GAPDH antibody (1:2,000, 60004-1-Ig; Proteintech) were used in this study.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Real-time Polymerase Chain Reaction

Effects of 15d-PGJ 2 on the anti-cancerous activities of topoisomerase inhibitors in RCC4 (-) cells . RCC4 (-) cells were treated with CPT (A), VP-16 (B), DOX (C) or 15d-PGJ 2 (D) at the indicated concentrations for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). *P < 0.05, compared with control, **P < 0.01, compared with control. (E) RCC4 (-) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence (open column) or presence (closed column) of 20 μM 15d-PGJ 2 for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). **P < 0.01, compared with control. (F) RCC4 (-) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence or presence of 20 μM 15d-PGJ 2 for 24 h. Morphologies were photographed by phase contrast. Scale bar = 100 µm.

Journal: Biochemistry and Biophysics Reports

Article Title: 15-deoxy-Δ 12, 14 -prostaglandin J 2 enhances anticancer activities independently of VHL status in renal cell carcinomas

doi: 10.1016/j.bbrep.2019.01.001

Figure Lengend Snippet: Effects of 15d-PGJ 2 on the anti-cancerous activities of topoisomerase inhibitors in RCC4 (-) cells . RCC4 (-) cells were treated with CPT (A), VP-16 (B), DOX (C) or 15d-PGJ 2 (D) at the indicated concentrations for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). *P < 0.05, compared with control, **P < 0.01, compared with control. (E) RCC4 (-) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence (open column) or presence (closed column) of 20 μM 15d-PGJ 2 for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). **P < 0.01, compared with control. (F) RCC4 (-) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence or presence of 20 μM 15d-PGJ 2 for 24 h. Morphologies were photographed by phase contrast. Scale bar = 100 µm.

Article Snippet: RCC4(+) and RCC4(-) cells were obtained from KAC Co. Ltd. (Kyoto, Japan).

Techniques: Activity Assay, Control

Effects of 15d-PGJ 2 on the anti-cancerous activities of topoisomerase inhibitors in RCC4 (+) cells. RCC4 (+) cells were treated with CPT (A), VP-16 (B), DOX (C) or 15d-PGJ 2 (D) at the indicated concentrations for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 3). *P < 0.05, compared with control, **P < 0.01, compared with control. (E) RCC4 (+) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence (open column) or presence (closed column) of 20 μM 15d-PGJ 2 for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). **P < 0.01, compared with control. ## P < 0.01, compared with each topoisomerase inhibitor alone. (F) RCC4 (+) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the 0.05 absence or presence of 20 μM 15d-PGJ 2 for 24 h. Morphologies were photographed by phase contrast. Scale bar = 100 µm.

Journal: Biochemistry and Biophysics Reports

Article Title: 15-deoxy-Δ 12, 14 -prostaglandin J 2 enhances anticancer activities independently of VHL status in renal cell carcinomas

doi: 10.1016/j.bbrep.2019.01.001

Figure Lengend Snippet: Effects of 15d-PGJ 2 on the anti-cancerous activities of topoisomerase inhibitors in RCC4 (+) cells. RCC4 (+) cells were treated with CPT (A), VP-16 (B), DOX (C) or 15d-PGJ 2 (D) at the indicated concentrations for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 3). *P < 0.05, compared with control, **P < 0.01, compared with control. (E) RCC4 (+) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the absence (open column) or presence (closed column) of 20 μM 15d-PGJ 2 for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). **P < 0.01, compared with control. ## P < 0.01, compared with each topoisomerase inhibitor alone. (F) RCC4 (+) cells were treated with 0.05 μM CPT, 20 μM VP-16 or 1 μM DOX in the 0.05 absence or presence of 20 μM 15d-PGJ 2 for 24 h. Morphologies were photographed by phase contrast. Scale bar = 100 µm.

Article Snippet: RCC4(+) and RCC4(-) cells were obtained from KAC Co. Ltd. (Kyoto, Japan).

Techniques: Activity Assay, Control